GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 271,752 shares, a decrease of 53.5% from the May 31st total of 584,471 shares. Currently, 7.9% of the company’s stock are short sold. Based on an average daily volume of 1,155,944 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

Several brokerages have weighed in on GOVX. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Trading Down 0.8%

Shares of GeoVax Labs stock traded down $0.01 during trading hours on Wednesday, hitting $1.26. 400,444 shares of the company were exchanged, compared to its average volume of 2,631,593. GeoVax Labs has a 1 year low of $0.96 and a 1 year high of $23.10. The business has a 50-day moving average of $1.63 and a 200-day moving average of $2.50. The stock has a market capitalization of $4.37 million, a price-to-earnings ratio of -0.07 and a beta of 3.62.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Wednesday, April 15th. The company reported $1.85 earnings per share for the quarter. As a group, research analysts anticipate that GeoVax Labs will post -8.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC acquired a new position in GeoVax Labs in the third quarter valued at $253,000. Jane Street Group LLC acquired a new stake in GeoVax Labs in the 4th quarter worth about $99,000. HRT Financial LP acquired a new stake in GeoVax Labs in the 4th quarter worth about $31,000. Renaissance Technologies LLC purchased a new stake in GeoVax Labs in the 4th quarter valued at about $104,000. Finally, Hudson Bay Capital Management LP purchased a new stake in GeoVax Labs in the 3rd quarter valued at about $47,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.